CN115583948A - Pol1抑制剂的新型晶体形式 - Google Patents

Pol1抑制剂的新型晶体形式 Download PDF

Info

Publication number
CN115583948A
CN115583948A CN202210899067.8A CN202210899067A CN115583948A CN 115583948 A CN115583948 A CN 115583948A CN 202210899067 A CN202210899067 A CN 202210899067A CN 115583948 A CN115583948 A CN 115583948A
Authority
CN
China
Prior art keywords
crystalline form
crystalline
compound
cancer
crystalline forms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210899067.8A
Other languages
English (en)
Chinese (zh)
Inventor
M·哈达彻
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pimera Inc
Original Assignee
Pimera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pimera Inc filed Critical Pimera Inc
Publication of CN115583948A publication Critical patent/CN115583948A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202210899067.8A 2017-03-28 2018-03-28 Pol1抑制剂的新型晶体形式 Pending CN115583948A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762477746P 2017-03-28 2017-03-28
US62/477,746 2017-03-28
US201762491635P 2017-04-28 2017-04-28
US62/491,635 2017-04-28
CN201880035566.4A CN110709400A (zh) 2017-03-28 2018-03-28 Pol1抑制剂的新型晶体形式
PCT/US2018/024898 WO2018183540A1 (en) 2017-03-28 2018-03-28 Novel crystal forms of a pol1 inhibitor

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880035566.4A Division CN110709400A (zh) 2017-03-28 2018-03-28 Pol1抑制剂的新型晶体形式

Publications (1)

Publication Number Publication Date
CN115583948A true CN115583948A (zh) 2023-01-10

Family

ID=63676829

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210899067.8A Pending CN115583948A (zh) 2017-03-28 2018-03-28 Pol1抑制剂的新型晶体形式
CN201880035566.4A Pending CN110709400A (zh) 2017-03-28 2018-03-28 Pol1抑制剂的新型晶体形式

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201880035566.4A Pending CN110709400A (zh) 2017-03-28 2018-03-28 Pol1抑制剂的新型晶体形式

Country Status (7)

Country Link
US (2) US11912706B2 (cg-RX-API-DMAC7.html)
EP (1) EP3601286A4 (cg-RX-API-DMAC7.html)
JP (3) JP2020512975A (cg-RX-API-DMAC7.html)
CN (2) CN115583948A (cg-RX-API-DMAC7.html)
BR (1) BR112019020058A2 (cg-RX-API-DMAC7.html)
CA (1) CA3057741A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018183540A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9758518B2 (en) 2015-03-04 2017-09-12 Pimera, Inc. Compositions, uses and methods for making them
JP2020512975A (ja) 2017-03-28 2020-04-30 ピメラ,インク. Pol1阻害剤の新規な結晶形態

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1042801A (en) 1909-10-28 1912-10-29 Isidor Kitsee Protecting kinematographic films.
NL7709746A (nl) 1976-09-09 1978-03-13 Hoechst Ag Werkwijze ter bereiding van benzimidazo-(1,2-a)-chi- nolinen.
DE2929414A1 (de) 1979-07-20 1981-02-05 Hoechst Ag Pyrimido- eckige klammer auf 5',4' zu 5,6 eckige klammer zu -pyrido- eckige klammer auf 1,2-a eckige klammer zu -benzimidazole, verfahren zu ihrer herstellung und deren verwendung
DE3502689A1 (de) 1985-01-26 1986-07-31 Hoechst Ag, 6230 Frankfurt Elektrophotographisches aufzeichnungsmaterial
DE19509043A1 (de) 1995-03-03 1996-09-05 Bayer Ag Cyanierung von Doppelbindungssystemen
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
AU1182702A (en) 2000-10-03 2002-04-15 Bristol Myers Squibb Co Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same
US7354916B2 (en) 2003-04-07 2008-04-08 Cylene Pharmaceuticals Substituted quinobenzoxazine analogs
JP2006522827A (ja) 2003-04-07 2006-10-05 サイリーン ファーマシューティカルズ インコーポレーティッド 置換キノベンゾオキサジン類似体
US7507727B2 (en) 2003-04-07 2009-03-24 Cylene Pharmaceuticals, Inc. Substituted quinobenzoxazine analogs and methods of using thereof
NZ553746A (en) 2004-09-17 2010-06-25 Cylene Pharmaceuticals Inc Quinolone analogs as cell proliferation inhibitors
US7652134B2 (en) 2004-09-17 2010-01-26 Cylene Pharmaceuticals, Inc. Methods for converting quinolone esters into quinolone amides
US7402579B2 (en) 2005-04-15 2008-07-22 Cylene Pharmaceuticals, Inc. Quinobenzoxazine analogs and compositions
EP1928887B1 (en) 2005-08-05 2014-12-17 Senhwa Biosciences, Inc. Methods of preparing quinolone analogs
WO2007038215A1 (en) 2005-09-22 2007-04-05 Incyte Corporation Tetracyclic inhibitors of janus kinases
WO2007125405A2 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
US20100063046A1 (en) 2006-05-17 2010-03-11 Whitten Jeffrey P Tetracyclic imidazole analogs
WO2008156879A1 (en) 2007-06-20 2008-12-24 Universal Display Corporation Blue phosphorescent imidazophenanthridine materials
KR101601332B1 (ko) 2007-10-05 2016-03-08 센화 바이오사이언시즈 인코포레이티드 퀴놀론 유사체 및 이와 관련된 방법
JP5576370B2 (ja) 2008-08-06 2014-08-20 ファイザー・インク Chk−1阻害剤としての6置換2−ヘテロシクリルアミノピラジン化合物
JP5801193B2 (ja) 2008-11-03 2015-10-28 エルジー・ケム・リミテッド 新しい含窒素複素環化合物およびそれを用いた有機電子素子
US8124770B2 (en) 2009-04-01 2012-02-28 Beatriz Zayas Fluorescent cellular markers
CN101781312B (zh) 2009-12-30 2012-09-26 中国科学院广州生物医药与健康研究院 一种吲哚衍生物的合成方法
WO2011156698A2 (en) 2010-06-11 2011-12-15 Abbott Laboratories NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS
KR101567610B1 (ko) 2010-11-04 2015-11-09 주식회사 엘지화학 신규한 질소 함유 헤테로환 화합물 및 이를 이용한 유기 전자 소자
SG11201400988SA (en) 2011-10-21 2014-07-30 Glaxosmithkline Llc Compounds and methods for enhancing innate immune responses
KR101561730B1 (ko) 2012-02-06 2015-10-22 주식회사 엘지화학 질소원소를 함유한 헤테로고리 유도체 및 이를 이용한 유기 전자 소자
EP3074391B1 (en) 2013-11-28 2019-07-31 Tel Hashomer Medical Research Infrastructure And Services Ltd. Rna polymerase i inhibitors and uses thereof
BR112016026150B1 (pt) 2014-05-09 2019-11-05 Pimera, Inc. compostos carboxílicos e seu uso na preparação de medicamentos ou composições farmacêuticas para tratar câncer
US9758518B2 (en) 2015-03-04 2017-09-12 Pimera, Inc. Compositions, uses and methods for making them
CN106349244B (zh) * 2015-07-13 2018-07-27 首都医科大学 苯并咪唑并喹唑啉二甲氧苯氧乙酰-AA-OBzl,其合成,活性和应用
CN119185322A (zh) 2015-11-20 2024-12-27 生华生物科技股份有限公司 用于治疗癌症的四环喹诺酮类似物组合疗法
JP2020512975A (ja) 2017-03-28 2020-04-30 ピメラ,インク. Pol1阻害剤の新規な結晶形態

Also Published As

Publication number Publication date
EP3601286A4 (en) 2020-09-23
BR112019020058A2 (pt) 2020-07-14
CN110709400A (zh) 2020-01-17
EP3601286A1 (en) 2020-02-05
US11912706B2 (en) 2024-02-27
US20230192694A1 (en) 2023-06-22
WO2018183540A1 (en) 2018-10-04
US20250243200A1 (en) 2025-07-31
JP2023126708A (ja) 2023-09-08
JP2020512975A (ja) 2020-04-30
JP2025060702A (ja) 2025-04-10
CA3057741A1 (en) 2018-10-04

Similar Documents

Publication Publication Date Title
JP6506779B2 (ja) 医薬化合物
CN105934434B (zh) Syk抑制剂
JP2025060702A (ja) Pol1阻害剤の新規な結晶形態
KR20170068597A (ko) 브로모도메인 저해제
US20250243206A1 (en) Crystalline forms of a phosphoinositide 3-kinase (pi3k) inhibitor
HK40020743A (en) Novel crystal forms of a pol1 inhibitor
US11267805B2 (en) Solid forms of (4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl) piperazine-1-yl)(1-hydroxycyclopropyl)methanone
HK40107642A (en) Crystalline forms of a phosphoinositide 3-kinase (pi3k) inhibitor
CA3178187A1 (en) Compounds for targeted degradation of interleukin-2-inducible t-cell kinase and methods of use
HK40057216A (en) Crystalline forms of a phosphoinositide 3-kinase (pi3k) inhibitor
HK40057216B (en) Crystalline forms of a phosphoinositide 3-kinase (pi3k) inhibitor
KR20230154382A (ko) 신규한 pim 키나아제 억제 화합물 및 이의 용도
EA044976B1 (ru) Кристаллические формы ингибитора фосфоинозитид 3-киназы (pi3k)
AU2007225206A1 (en) Polymorphs of N-(4-chloro-3-methyl-5-isoxazolyl)2-[2-methyl-4,5-(methylenedioxy) phenylacetyl]thiophene-3-sulfonamide, sodium salt
WO2012115066A1 (ja) グリシントランスポーター阻害物質
HK1223101B (en) Polymorphs of gdc-0032, methods of production, and pharmaceutical uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination